U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp’s heart drug said on Friday they did not believe the benefits offered by the therapy outweighed its risks, sending the company’s shares down 14%. The drug, Brinavess, approved in several other counties including Europe and Canada, aims to correct erratic heart rhythm in the upper chambers of the heart due to a condition known as atrial fibrillation or AFib. Although Correvio has provided sufficient evidence of the drug’s benefit, Brinavess comes with “serious liabilities” including low blood pressure, irregular heartbeats in the lower heart chambers, and death, the …read more
Source:: Yahoo Finance
